Welcome to our dedicated page for Merck & Co. SEC filings (Ticker: MRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Merck & Co.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Merck & Co.'s regulatory disclosures and financial reporting.
Merck & Co., Inc. executive David Michael Williams reported routine equity compensation activity involving restricted stock units and related tax withholding. He exercised 1,377 restricted stock units into the same number of common shares at a stated value of $110.03 per share and 679 common shares were disposed of to cover tax obligations.
Following these transactions, he directly held 31,716.037 shares of Merck common stock. He also held 2,755 restricted stock units, each representing a contingent right to receive one Merck common share, which are scheduled to vest and be distributed in three equal installments on April 29, 2026, April 29, 2027 and April 29, 2028. Holdings include shares acquired through dividend reinvestment.
Merck & Co., Inc. senior vice president Dalton E. Smart III reported routine equity compensation activity. On April 29–30, 2026, he exercised restricted stock units covering 1,408 shares of common stock, converting them into directly held shares.
Across these transactions, 483 shares of common stock were withheld at prices of $110.03 and $110.95 per share to satisfy tax obligations, so they were not open-market sales. Following the transactions, he directly holds 9,137.315 shares of Merck common stock.
Footnotes show he also holds 1,889 restricted stock units, each representing a contingent right to one share of Merck common stock. These units vest and are distributed in three equal installments on 4/29/2026, 4/29/2027, 4/29/2028, and on 4/30/2025, 4/30/2026, and 4/30/2027.
Merck & Co., Inc. Executive VP & President, MRL, Dean Y. Li exercised restricted stock units and settled related taxes in shares. On April 29, 2026, 4,722 restricted stock units converted into the same number of common shares, while 2,326 shares were withheld to cover tax obligations at $110.03 per share.
After these transactions, Li directly owned 94,431.05 shares of Merck common stock and held 9,444 restricted stock units outstanding. The RSUs vest and are distributed in three equal installments on April 29, 2026, April 29, 2027, and April 29, 2028.
Merck & Co., Inc. EVP and General Counsel Jennifer Zachary reported compensation-related equity transactions. On 4/29/2026, she exercised 2,951 restricted stock units into an equal number of Merck common shares. In a related move, 1,454 common shares were disposed of to cover tax obligations.
Following the derivative exercise, one transaction line shows 72,351.254 common shares owned directly, while another reflects 70,897.254 shares after the tax-withholding disposition. Footnotes explain that each restricted stock unit represents a contingent right to one Merck share and that these units vest in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028.
Merck & Co., Inc. executive vice president and Chief HR Officer Betty D. Larson reported routine equity compensation activity over two days. She exercised restricted stock units to acquire 13,435 shares of common stock at reference prices of $110.95 and $110.03 per share, and 5,858 shares were disposed of to cover tax obligations through share withholding rather than open-market sales.
Following these transactions, Larson directly owned 13,774 shares of Merck common stock. The filing reflects compensation-related derivative exercises and associated tax-withholding dispositions, without any open-market buying or selling.
Merck & Co., Inc. Executive Vice President and CFO Caroline Litchfield reported routine equity compensation activity. She exercised 3,935 restricted stock units, converting them into the same number of common shares at a stated value of $110.03 per share. To cover tax obligations, 1,938 common shares were disposed of in a tax-withholding transaction, rather than an open-market sale. After these transactions, she directly holds about 94,238.657 common shares and 7,870 restricted stock units that continue to vest over time. Footnotes indicate her holdings also include shares acquired through dividend reinvestment.
Merck & Co., Inc. Chairman, CEO & President Robert M. Davis reported routine equity compensation activity. On 4/29/2026, he exercised 13,300 restricted stock units into common shares at a reported value of $110.03 per share, while 6,551 shares were withheld to cover tax obligations. Following these transactions, he directly held about 450,350.757 shares of Merck common stock and 26,601 restricted stock units. The remaining restricted stock units vest and are distributed in equal installments on 4/29/2027 and 4/29/2028.
Merck & Co., Inc. executive vice president for Oncology & International, Johannes Jacobus Oosthuizen, reported routine equity compensation activity. He exercised 1,377 Restricted Stock Units (RSUs), converting them into the same number of Merck common shares at a reported value of $110.03 per share. To cover tax obligations, 679 common shares were disposed of through a tax-withholding transaction rather than an open-market sale. Following these transactions, Oosthuizen directly holds about 21,895.389 common shares. Footnotes state that each RSU represents a contingent right to one share of common stock and that the RSUs vest in three equal installments on 4/29/2026, 4/29/2027, and 4/29/2028, highlighting that this event is part of an ongoing vesting schedule.
Merck & Co Inc: Vanguard Capital Management reports beneficial ownership of 186,323,766 shares of Common Stock, representing 7.53% of the class. The filing shows sole voting power for 25,336,142 shares and sole dispositive power for 186,323,766 shares. The report is signed on 04/30/2026 and describes holdings exercised by Vanguard Capital Management LLC and specified affiliates under SEC Release No. 34-39538.
Merck & Co., Inc. reported a first-quarter 2026 net loss driven by a large acquisition charge, despite solid sales growth. Sales were $16.286 billion, up 5% from $15.529 billion, led by oncology products such as KEYTRUDA, which generated $8.034 billion, up 12%, and strong 13% growth in Animal Health.
GAAP net loss attributable to Merck was $4.240 billion, or a loss of $1.72 per diluted share, versus earnings of $2.01 per share a year earlier. Non-GAAP loss per share was $1.28, compared with non-GAAP earnings of $2.22. Both GAAP and non-GAAP results were heavily affected by a $9.0 billion charge, equal to $3.62 per share, for the acquisition of Cidara Therapeutics.
Vaccines and diabetes franchises faced headwinds, with GARDASIL/GARDASIL 9 sales down 19% to $1.069 billion and JANUVIA/JANUMET down 28% to $574 million. Merck updated its 2026 outlook to forecast sales of $65.8 billion to $67.0 billion and non-GAAP EPS of $5.04 to $5.16, including the Cidara charge. A separate tender offer to acquire Terns is expected to be accounted for as an asset acquisition, resulting in an additional one-time charge of approximately $5.8 billion, or about $2.35 per share, plus an estimated $0.12 EPS impact over the remainder of 2026 after closing.